Metastatic Lesion of the Vertebra in Prostate Cancer and Complex Instrumental Diagnostics
https://doi.org/10.37174/2587-7593-2021-4-2-101-107
Abstract
Purpose: To conduct a retrospective analysis of the clinical case of metastatic vertebral lesion in prostate cancer and the algorithm for the use of instrumental diagnostic methods.
Material and methods: Patient 67 years old. History of prostatectomy for prostate cancer. Suspected metastatic lesion of the left transverse process of the 7th thoracic vertebra based on PET/CT. For clarification, MRI, Skeletal scintigraphy, SPECT/CT were performed.
Conclusion: Access to a wide range of instrumental methods does not guarantee correct diagnosis. Modality, research methodology, time between the first and clarifying methods — all these factors affect the correct diagnosis, the choice of the treatment method, the timeliness of the start of treatment and, as a result, the fate of the patient.
About the Authors
N. V. Kochergina
N.N. Blokhin National Medical Research Center of Oncology;
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoye Highway, Moscow, Russia 115478;
Build. 1, 2/1 Barrikadnaya St., Moscow, Russia 125993
S. N. Prokhorov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
24 Kashirskoye Highway, Moscow, Russia 115478
S. I. Tkachev
N.N. Blokhin National Medical Research Center of Oncology;
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoye Highway, Moscow, Russia 115478;
Build. 1, 2/1 Barrikadnaya St., Moscow, Russia 125993
A. D. Ryzhkov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
24 Kashirskoye Highway, Moscow, Russia 115478
A. B. Bludov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
24 Kashirskoye Highway, Moscow, Russia 115478;
References
1. Bray F, Ferley F, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394424. DOI: 10.3322/caac.21492.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. DOI: 10.3322/caac.21442.
3. Axel EM, Matveev VB. Statistics of Malignant Tumors of Urinary and Male Urogenital Organs in Russia and the Countries of the Former USSR. Oncourology. 2019;15(2):15-24. (In Russian).
4. Kochergina NV, Prokhorov SN, Bludov AB, et al. The Effectiveness of MRI in Determining the Presence of Bone Metastases in a Controversial Result of SPECT/CT. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2020;3(3):93-100. (In Russian). DOI: 10.37174/25877593-2020-3-3-93-100
5. Turpin A, Girard E, Baillet C, et al. Imaging for Metastasis in Prostate Cancer: A Review of the Literature. Front Oncol. 2020 Jan 31;10:55. DOI: 10.3389/fonc.2020.00055
6. Ryzhkov AD, Krylov AS, Shchipakhina YA, et al. Diagnostics of Skeletal Metastases with Using SPECT/CT. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2018;1(3):21-6. (In Russian). DOI: 10.37174/2587-7593-2018-1-3-21-26.
7. Kuji I, Yamane T, Seto A, et al. Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer. Eur J Hybrid Imaging. 2017;1(1):2. DOI: 10.1186/s41824017-0006-y.
8. Giesel FL, Will L, Lawal I, et al. Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J Nucl Med. 2018 Jul;59(7):1076-80. DOI: 10.2967/jnumed.117.204669. Epub 2017 Dec 21. PMID: 29269569.
9. Pianou NK, Stavrou PZ, Vlontzou E, et al. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. DOI: 10.1967/s002449910952. Epub 2019 Mar 7. PMID: 30843003.
10. Siva S, Bressel M, Murphy DG, et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. Eur Urol. 2018 Oct;74(4):455-62. DOI: 10.1016/j.eururo.2018.06.004.
Review
For citations:
Kochergina N.V., Prokhorov S.N., Tkachev S.I., Ryzhkov A.D., Bludov A.B. Metastatic Lesion of the Vertebra in Prostate Cancer and Complex Instrumental Diagnostics. Journal of oncology: diagnostic radiology and radiotherapy. 2021;4(2):101-107. (In Russ.) https://doi.org/10.37174/2587-7593-2021-4-2-101-107
Views:
424
Email this article 